Journal of Cancer Genetics And Biomarkers

Dr. Joshua Curtin, Oncology Drug Discovery,
Research and Development,
Bristol-Myers Squibb
Editorial Board

Dr. Joshua Curtin

Oncology Drug Discovery, Research and Development, Bristol-Myers Squibb · United States

Editorial leadership for Journal of Cancer Genetics And Biomarkers ISSN 2572-3030

Research interests

  • Cancer Biologist
  • Drug Discovery Expert

Biography

  • Highly motivated drug discovery scientist with a proven record identifying and evaluating oncology and immuno-oncology targets. 
  • Successful program manager with a track record of target identification, validation, and development utilizing small molecules and biologics. 
  • Effective leadership and matrixing skills, orchestrating efforts across multiple functional areas to leverage technology and drive efficient science. 
  • Innovative and versatile scientist with proven ability to quickly adapt and embrace new scientific paradigms. 
  • Expertise in Immuno-Oncology, with an emphasis on intracellular signaling mechanisms, anti-tumor immunity, immune infiltrates, T cell activation, purinergic and immunosuppressive mechanisms and informed combinatorial therapeutic approaches. 
  • Expertise in tumor cell biology, with an emphasis on developmental signaling pathways, mechanisms of signal transduction, transcriptional and epigenetic regulation. 
  • Extensive experience working collaboratively and mentoring colleagues and junior team members. 
  • Excellent communication skills and numerous peer-reviewed publications.

Considering JCGB for your work?

This journal is guided by Dr. Joshua Curtin (Oncology Drug Discovery, Research and Development, Bristol-Myers Squibb) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.

Start your submission

Menu